Impact of Isoniazid Chemo Prophylaxis on the incidence of Tuberculosis and the mortality rate in patients on antiretroviral treatment at the Reference Health Center of Commune II of Bamako from 2016 to 2020

Introduction: Tuberculosis (TB) is the leading cause of death among HIV-positive people. In Mali, the National Strategic Framework for the fight against HIV had planned to reduce mortality among people living with HIV (PLHIV) by 50% by 2017 through preventive treatment with isoniazid (IPT). The objective of this study was to assess the impact of IPT on TB incidence and mortality rates among PHAs. Methodology: This was a retrospective cohort study carried out at the Reference Health Centre of Commune II. Concerning the monitoring data of PLHIV from 2015, our reference and those from 2016 to 2020, the period of effectiveness of the TPI. The Preventive Fraction in Expos was used to measure the effectiveness of IPT and logistic regression to determine factors associated with the occurrence of death. Results: Among the 122 patients included between May and October 2020, the median age was 37 years, the sex ratio 2.5 in favor of women. The IPT was 94% effective [0.76 - 0.99]. Age (p=0.008 [0.911 - 0.986]), and BMI (p=0.011 [1.046 - 1.407]) were associated with the occurrence of death among PHAs. Conclusion: IPT has reduced deaths and reversed HIV/TB co-infection. This is why we suggest that the supervisory authority carry out a national impact assessment of the CFI. Keywords: Impact, Isoniazid chemoprophylaxis, PLHIV, CSRef CII of Bamako, HIV/TB.